In patients with diabetes mellitus who experience erectile dysfunction, what are the clinical considerations when selecting and managing phosphodiesterase type 5 inhibitors? Specifically, how do factors such as glycemic control, the presence of diabetic complications (e.g., neuropathy and vascular disease), and cardiovascular comorbidities influence the safety, efficacy, and dosing of these medications? Additionally, are there emerging therapeutic strategies or combination treatments that have demonstrated improved outcomes in this population? A discussion highlighting any recent evidence or guidelines, along with personal clinical experiences, would be appreciated.
Ed Meds For Diabetes